A Study of MLN0264 in Patients With Pancreatic Cancer

NCT02202785 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision, No Safety or Efficacy Concerns

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: MLN0264

Sponsor

Millennium Pharmaceuticals, Inc.